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Abstract
Objective: Examine whether false-positive HIV enzyme immunoassay (EIA) test results occur more frequently among
pregnant women than among women who are not pregnant and men (others).
Design: To obtain a large number of pregnant women and others tested for HIV, we identified specimens tested at a
national laboratory using Genetic Systems HIV-1/HIV-2 Plus O EIA from July 2007 to June 2008.
Methods: Specimens with EIA repeatedly reactive and Western blot-negative or indeterminate results were considered EIA
false-positive. We compared the false-positive rate among uninfected pregnant women and others, adjusting for HIV
prevalence. Among all reactive EIAs, we evaluated the proportion of false-positives, positive predictive value (PPV), and
Western blot bands among indeterminates, by pregnancy status.
Results: HIV prevalence was 0.06% among 921,438 pregnant women and 1.34% among 1,103,961 others. The false-positive
rate was lower for pregnant women than others (0.14% vs. 0.21%, odds ratio 0.65 [95% confidence interval 0.61, 0.70]).
Pregnant women with reactive EIAs were more likely than others (p,0.01) to have Western blot-negative (52.9% vs. 9.8%)
and indeterminate results (17.0% vs. 3.7%) and lower PPV (30% vs. 87%). The p24 band was detected more often among
pregnant women (p,0.01).
Conclusions: False-positive HIV EIA results were rare and occurred less frequently among pregnant women than others.
Pregnant women with reactive EIAs were more likely to have negative and indeterminate Western blot results due to lower
HIV prevalence and higher p24 reactivity, respectively. Indeterminate results may complicate clinical management during
pregnancy. Alternative methods are needed to rule out infection in persons with reactive EIAs from low prevalence
populations.
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Introduction
Universal screening to identify HIV infection in pregnant
women is recommended so that infected women can be linked to
care, start prophylaxis, plan for delivery, and avoid transmission
through breastfeeding [1–4]. Screening is often conducted using a
laboratory-based testing algorithm that incorporates enzyme
immunoassays (EIAs) which have been approved by the Food
and Drug Administration (FDA). These EIAs are highly sensitive
and specific, but there is a perception that pregnant women are at
higher risk for false-positive results [5,6]. If this perception is
shared by clinicians, they may be less likely to adopt universal
screening. False-positive HIV screening test results occur when a
repeatedly reactive EIA is followed by a negative or indeterminate
confirmatory test result in someone who is not infected. A person
whose specimen exhibits a repeatedly reactive EIA and negative
confirmatory test is likely not infected, and follow-up testing should
be based on risk behaviors [7]. Persons with an indeterminate
Western blot who are at low risk for HIV infection, including most
pregnant women in the United States, are often uninfected [8].
Persons with indeterminate results should be re-tested to resolve
infection status a month after the initial Western blot, and if
possible, pregnant women need to resolve their infection status
before entering labor to plan for delivery if infected [3,7]. False-
positive HIV antibody test results can occur in the absence of
infection due to cross-reactivity between viral proteins and tested
specimens, but such cross-reactivity is less common using current
peptide-based EIAs which contain fewer antigens than previous
viral lysate-based EIAs [9].
Although a previous study indicated that parity is associated
with false-positive HIV test results [10], it is not clear whether
being pregnant at the time of an HIV test is associated. One study
did not find pregnancy to be associated with indeterminate
Western blot results in uninfected persons, but its power to detect
an association was low [10]. Recent studies have evaluated EIA
test performance among women in labor [11,12]. These studies
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16538did not examine test specificity, which is inversely related to the
proportion of false-positive results, among persons who were not
pregnant. However, the confidence intervals for specificity for all
EIA tests used on pregnant women, including rapid tests,
overlapped the specificity figures listed in the FDA-cleared
package inserts, which presumably used a non-pregnant popula-
tion [11,12] to determine assay performance. These studies suggest
that the false-positive rate in pregnant women may not differ from
that in non-pregnant persons, but they were not designed to make
that comparison. Understanding the rate of false-positive EIA
results in pregnant women is also necessary to gauge whether
alternative algorithms, such as dual EIA algorithms, could be used
in this population [13]. In order to evaluate the occurrence of
false-positive HIV antibody test results in pregnant women
compared with others tested for HIV, we retrospectively evaluated
over three million HIV test results from laboratories operated by a
large U.S. commercial laboratory, which is believed to be the
largest such examination conducted to date.
Methods
We retrospectively collected testing data without personal
identifiers from serum and plasma specimens from persons 12
years of age and older that had been tested using the peptide-based
Genetic Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad, Redmond,
Washington) at laboratories operated by a national laboratory
from July 1, 2007, through June 30, 2008. Specimens with
repeatedly reactive EIA results had been tested using the Genetic
Systems HIV-1 Western blot kit (Bio-Rad, Redmond, Washing-
ton). EIA and Western blot tests were conducted according to
manufacturer instructions. Specimens were categorized by preg-
nancy status based on whether they were obtained from persons
who were pregnant, not pregnant, or persons for whom pregnancy
status was unknown. A specimen was considered to be from a
woman who was pregnant on the day the blood was collected for
GS EIA testing if at least one of the following criteria was met: i)
positive urine or serum human chorionic gonadotropin (HCG)-
based pregnancy test, ii) a simultaneous request for either a
cytogenetic test, a maternal serum screen panel, rubella serology as
part of an obstetric panel, a one-hour glucose tolerance test for
gestational diabetes, or iii) provision of an ICD-9 code for normal
pregnancy or high-risk pregnancy or other pregnancy-related
ICD-9 code. A specimen was categorized as being from a person
who was non-pregnant when it was from: i) a male, ii) a female
with a negative pregnancy test or ICD-9 code for a negative
pregnancy test; iii) a woman age 55 or over, or iv) a female with an
unspecified age who did not meet the above described pregnancy
criteria. Specimens were categorized as being from a person whose
pregnancy status was unknown when either: i) a female did not
meet any of the pregnant or non-pregnant criteria listed above, ii)
the submitted test requisition specified the individual as a male,
but they simultaneously met one of the pregnancy-related criteria,
or iii) gender was not specified. Criteria for these categories were
based on discussions with staff from the American College of
Obstetrics and Gynecologists coding department. Further, in a
prospective study conducted at the same laboratories, all
specimens from persons categorized as pregnant using these
criteria (n=474) were found to be pregnant on a quantitative
HCG pregnancy test and 1430/1431 (99.93%) labeled as not
pregnant using these criteria were found not to be pregnant using
a quantitative HCG pregnancy test.
The number and percent of specimens with HIV test results in
each of the following HIV infection categories were quantified.
Specimens with HIV-negative EIA results were considered
uninfected. Specimens with a repeatedly reactive EIA and positive
Western blot were considered HIV-infected. A false-positive HIV
test result was defined as a repeatedly reactive EIA followed by a
negative or indeterminate Western blot result. The false-positive
rate was defined as [# false-positive/# uninfected persons] where
uninfected persons were considered those who were EIA-negative
and those with false-positive results. The false-positive rate is
equivalent to [1-specificity]. The false-positive rate was compared
for: i) pregnant women versus persons who were non-pregnant, ii)
for pregnant women versus women of reproductive age (12 to 55
years) who were non-pregnant, and iii) for pregnant women versus
persons whose pregnancy status was unknown. We also examined
the false-positive rate by the following co-factors: age, month of
testing, and laboratory facility. Race/ethnicity data were not
available. We analyzed the risk of false-positive HIV test result for
pregnant women compared to persons who were not pregnant
using a Mantel Haenszel odds ratio (OR) which was adjusted for
HIV prevalence at each laboratory facility. The Centers for
Disease Control and Prevention (CDC) received de-identified
study data in aggregate, so multivariable regression techniques to
adjust for co-factors beyond HIV prevalence at laboratories, which
were related to pregnancy and false-positive HIV EIA test results,
could not be performed.
Among all specimens with repeatedly reactive EIAs, we
evaluated the proportion of specimens that were Western blot-
negative, indeterminate, or positive, and the positive predictive
value of the EIA test, by pregnancy status. Among those with
Western blot-indeterminate results, we evaluated whether anti-
body reactivity to specific HIV polypeptide bands was detected
more frequently among pregnant women than others. Statistical
comparisons were made using the chi-square test to assess the
difference between two proportions. The statistical software
package SAS v9.1 (Cary, NC) was used for data analysis.
Since the laboratory dataset was based on distinct patient
encounters, individuals may have been included in the analysis
dataset more than once (i.e., if they had multiple blood collection
events). It is unlikely that persons with EIA negative results had
more than one test result during the analysis period, with the
possible exception of pregnant women from areas of high HIV
prevalence [2]. We assessed whether persons with a false-positive
result had follow-up HIV testing by July 2008, by pregnancy
status. A person was identified as having a follow-up specimen if
name, date of birth and gender were the same as for the initial
specimen because no additional patient identifiers were available.
Among persons with repeatedly reactive EIAs and negative or
indeterminate Western blot results, we assessed whether the
follow-up test result was Western blot-positive within a month after
the false-positive result. The one-month period was chosen to
assess whether persons designated as having false-positive results
appeared to have been infected at the time of that initial test,
because most persons with indeterminate results who are infected
with HIV-1 will develop detectable antibody within that one
month follow up period [7,14]. It is not known whether persons
with false-positive HIV- 1/2 antibody EIA results had RNA or
DNA testing to resolve infection status.
Probabilistic sensitivity analyses with 10,000 repetitions were
conducted to evaluate the false-positive rate among pregnant
women assuming that the proportion of specimens from persons of
unknown pregnancy status to be categorized as pregnant was
binomially distributed [15]. This proportion was estimated to be
23% based on data from a prospective study at the same
commercial laboratory (data not shown). Probabilistic sensitivity
analyses with 10,000 repetitions were also conducted to evaluate
the false-positive rate among non-pregnant persons after (1) re-
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pregnant as described above and (2) removing specimens with
EIA false-positive results that were potentially infected. The
proportion of potentially infected non-pregnant persons with
repeatedly-reactive EIA and Western blot-negative specimens
removed from analysis was sampled from a triangular distribution
with a mode equal to the percent of repeatedly reactive EIA and
Western blot-negative specimens with follow-up results that were
Western blot-positive (18%), and with range based on plausible
values from the literature (0.05% to 25%) [16]. Likewise, the
proportion of potentially infected non-pregnant persons with
repeatedly reactive EIA and indeterminate Western blot results
removed from analysis was also selected from a triangular
distribution with mode equal to the proportion with follow-up
results that were Western blot-positive (35%), and with range
based on plausible values from the literature (0.05% to 40%) [16–
18]. In order to examine how the false-positive rate among non-
pregnants would be impacted if a much greater proportion of
those designated as false-positive were actually infected than that
observed among those with follow-up HIV testing, we assessed the
false-positive rate after doubling the mode values (i.e.,
mode=36% in the EIA-repeatedly reactive and Western blot-
negative group and mode=70% in the Western blot-indetermi-
nate group).
This study was determined to be research not involving
identifiable human subjects by the National Center for HIV,
Viral Hepatitis, STD, and TB Prevention at the Centers for
Disease Control and Prevention. According to HIPPA regulations,
protected health information can be disclosed, without the written
authorization of the individual, to a public health entity for public
health activities and purposes, such as this investigation. For this
project, a laboratory shared health information (test results),
without personal identifiers, with CDC.
Results
During the analysis period, 3,357,200 specimens had an EIA
test result. Of those, 921,501 (27.5%) were from pregnant women,
1,104,118 (32.9%) were from persons who were non-pregnant,
and 1,331,581 (39.7%) were from persons whose pregnancy status
was unknown (Table 1). The criteria identified most frequently for
those categorized as pregnant was an ICD-9 code for normal or
high-risk pregnancy (80.3%) and for those categorized as not
pregnant was being male (87.4%) (Table 1).
Of 3,356,764 (99.9%) specimens with interpretable HIV test
results, 541 (0.06%) of 921,438 from pregnant women and 14,788
(1.34%) of 1,103,961 from persons who were non-pregnant were
Western blot-positive (Table 2). The false-positive HIV EIA rate
for pregnant women was lower than for persons who were non-
pregnant (0.14% vs. 0.21%, p,0.01), and it was lower for
pregnant women than for persons of unknown pregnancy status
(0.14% vs. 0.18%, p,0.01) (Table 2). The false-positive HIV EIA
rate for pregnant women (0.14%) was not different than that for
women of reproductive age who were non-pregnant [0.15%, (74/
50,565), p=0.56].
The false-positive rate was lower in those study subjects who
were the median age of 30.2 years or younger [0.17% (2,789/
1,646,060)] compared with those who were older than 30.2
[0.19% (3,056/1,651,993), p,0.01]. The median monthly HIV
EIA false-positive rate for this one-year study period was 0.17%,
and ranged from 0.16% to 0.21%. The occurrence of false-
positives did not appear to be seasonal (not shown). The median
false-positive rate by individual laboratory facility was 0.14%
(range 0.04% to 0.65%). The two laboratory facilities with the
highest HIV EIA false-positive rates function primarily as
reference laboratories for hospitals and other facilities, and are
more likely to receive specimens that initially screened HIV-
repeatedly reactive than those tested at other regional facilities
within the same laboratory system. The HIV prevalence at the
laboratory facilities ranged from 0.17% to 2.8%, and the two
reference laboratories mentioned previously had the highest
prevalence rates. After adjusting for prevalence at each laboratory
facility, pregnant women were less likely to have false-positive
screening test results than non-pregnant persons [adjusted OR
0.65, 95% confidence interval (CI) (0.61, 0.70)] (Table 2).
Among all specimens with repeatedly reactive HIV EIA results,
those from pregnant women were more likely to test Western blot-
negative and indeterminate than those from persons who were not
pregnant (52.9% vs. 9.8%, p,0.01) and (17.0% vs. 3.7%,
p,0.01), respectively (Table 3). Among persons with indetermi-
nate Western blot results, the only band detected more often
among pregnant women than among persons who were not
pregnant was the p24 band (79% vs. 68%, p,0.01). The positive
predictive value of the HIV EIA test among pregnant women was
lower than that among persons who were not pregnant (30% vs.
86.5%, p,0.01) (Table 3).
Of 4,329 specimens with repeatedly reactive EIA and Western
blot-negative results, 346 (8.0%) had at least one follow-up testing
event by July 2008: 106/951 (11.2%) pregnant females, 119/1675
(7.1%) non-pregnant persons, and 121/1703 (7.1%) persons with
unknown pregnancy status. Of those with follow-up test results
Table 1. Pregnancy status of persons with specimens tested
at a national commercial laboratory using Genetic Systems
HIV-1/HIV-2 Plus O EIA (n=3,357,200); July 2007 to June 2008.
Pregnancy Status Pregnancy Status Criteria
a N( % )
Pregnant
Positive HCG test 31,897 (3.5)
Cytogenetic tests 5 (0)
Maternal serum screens 1,796 (0.2)
ICD-9 codes for pregnancy 739,869 (80.3)
Rubella test on obstetric panel 72,155 (7.8)
One-hour glucose challenge test 3,101 (0.3)
Other ICD-9 codes 72,678 (7.9)
Total pregnant 921,501
Not pregnant
Males 964,592 (87.4)
Females with negative HCG test 50,559 (4.6)
Females with ICD-9 code 72.41
b 192 (0)
Females age 55 and over 88,416 (8.0)
Females age unknown 359 (0)
Total not pregnant 1,104,118 (32.9)
Pregnancy Unknown
Females unknown pregnancy status 1,292,938 (97.1)
Gender not specified 36,133 (2.7)
Coded as males and pregnant 2,510 (0.2)
Total Pregnancy Unknown 1,331,581 (39.7)
aCriteria used to establish pregnancy status are listed in the order they were
evaluated.
bNegative pregnancy test result.
doi:10.1371/journal.pone.0016538.t001
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blot-negative result, fewer pregnant women than non-pregnant
persons had a Western blot-positive result [0/54 (0%) vs. 12/56
(21.4%), p,0.01]. Nine non-pregnant persons and no pregnant
women had follow-up results between 31 days and one year that
were Western blot-positive.
Of 1,640 specimens with repeatedly-reactive HIV EIA and
Western blot-indeterminate results, 187 (11.4%) had at least one
follow-up testing event by July 2008: 70/306 (22.9%) pregnant
women, 57/633 (9.0%) non-pregnant, and 60/701 (8.6%)
unknown pregnancy status. Slightly more than half (57.2%) of
the persons with follow-up test results within a month after the
initial indeterminate Western blot result had follow-up testing.
Fewer pregnant women than non-pregnant persons had a positive
Western blot result within one month of their indeterminate result
[(0/39 (0%) vs. 13/34 (38.2%), p,0.01]. Two pregnant women
and seven non-pregnant persons with initial results that were
indeterminate had follow-up results between 31 days and one year
that were Western blot-positive.
Following the sensitivity analysis in which specimens were re-
categorized as pregnant from the pregnancy-unknown category,
the false-positive rate among pregnant persons was 0.15%. After
specimens were categorized as non-pregnant from the pregnancy-
unknown category and approximately 18% (21/119) of repeatedly
reactive EIA and Western blot-negative and 35% (20/57) of
indeterminate specimens were reclassified because they may have
represented true infections, the false-positive rate among non-
pregnant persons was 0.16%. If the proportion misclassified as
false-positive were twice the rate observed among those designated
as false-positive with follow-up testing, the false-positive rate
among non-pregnant persons would be higher than 0.15%, the
false-positive EIA rate among pregnant women based on this
sensitivity analysis.
Discussion
We examined over three million HIV EIA test results and found
that false-positive results were rare (less than two in a thousand)
and occurred at a rate similar to that described in the
manufacturer’s package insert (Bio-Rad, Redmond, Washington).
Further, they occurred less frequently among persons who were
pregnant (0.14%) than among persons who were not pregnant
(0.21%). It is possible that the false-positive rate was higher in non-
pregnant persons because some were actually infected, and in the
process of seroconversion, particularly non-pregnant persons with
indeterminate results showing viral bands who reside in areas of
high prevalence and have other risk factors for HIV. Ideally, truly
HIV-infected persons would have positive confirmatory results
instead of indeterminate Western blot results, but new EIAs can
detect infections earlier than the Western blot develops the bands
needed to be considered positive [19]. Nevertheless, when the
proportion of specimens found to be infected on follow-up were
removed, pregnant women were not more likely to have false-
positive HIV EIA test results than others testing for HIV, as
previously thought. Basing the proportion of false-positives among
non-pregnants misclassified as infected on those with follow-up
testing is likely to artificially reduce the number classified as false-
positive because those with follow-up are more likely to be infected
than those without it. The observed difference in the false-positive
rate by pregnancy status, which amounts to less than one false-
positive result per one thousand tests, could also be explained by
observed differences in the false-positive rate by laboratory or
other unmeasured characteristics such as a concurrent medical
condition.
In this study and others, repeatedly reactive HIV EIA results
were unlikely to be indicative of HIV infection in pregnant women
Table 2. HIV test results, false-positive rate and risk of false-positive result, by pregnancy status
a, national commercial laboratory,
July 2007 to June 2008.
EIA
non-reactive
N( % )
Repeatedly-reactive EIA
Western blot- positive
N( % )
Repeatedly
reactive EIA
Western blot-
negative
N(%)
Repeatedly
reactive EIA
Western blot-
indeterminate
N(%)
False positive
rate
b
Crude odds ratio
(95% CI)
Adjusted
odds ratio
c
(95% CI)
Pregnant 919,640 (99.8) 541
(0.06)
951
(0.10)
306
(0.03)
0.14% 0.65
(0.60, 0.69)
0.65
(0.61, 0.70)
Not Pregnant 1,086,865 (98.5) 14,788 (1.34) 1,675
(0.15)
633
(0.06)
0.21% Reference Reference
Pregnancy
Unknown
1,324,344 (99.5) 4,617
(0.35)
1,703
(0.13)
701
(0.05)
0.18% 0.86
(0.81, 0.91)
0.85
(0.80, 0.90)
aExcludes 436 with uninterpretable Western blots or repeatedly-reactive EIA with Western blot not performed.
bFalse positive=EIA repeatedly-reactive and Western blot negative or indeterminate
False positive rate= [false-positive/(EIA-non-reactive + false-positive)].
cAdjusted for laboratory HIV prevalence.
doi:10.1371/journal.pone.0016538.t002
Table 3. Among specimens with a repeatedly-reactive EIA,
Western blot result and positive predictive value, by
pregnancy status
a; national commercial laboratory, July 2007
to June 2008.
Pregnant
N(%)
Not Pregnant
N(%) p-value
Western blot result
Negative 951 (52.9) 1,675 (9.8) p,0.01
Indeterminate 306 (17.0) 633 (3.7) p,0.01
Positive 541 (30.0)
b 14,788 (86.5)
b p,0.01
Total 1,798 17,096
aExcludes 436 with uninterpretable Western blots or repeatedly-reactive EIAs
with Western blot not performed.
bPositive predictive value.
doi:10.1371/journal.pone.0016538.t003
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proportion of reactive tests which are false positive increases
because there are fewer infected persons in the population being
tested. In this study, pregnant women with indeterminate Western
blot results were often uninfected, based on data from a limited
number of women with follow-up tests and the low prevalence of
HIV infection in this population. Indeterminate Western blots
among pregnant women frequently displayed reactivity with the
p24 band, a band often observed in individuals with low risk of
infection (8). Recommendations for testing following an indeter-
minate Western blot include conducting a Western blot or indirect
immunofluorescence assay on a second sample at least one month
after the indeterminate result, or testing for the presence of HIV
nucleic acids [7]. Obtaining testing several weeks after an initial
indeterminate Western blot result may not be practical for
pregnant women, as evidenced by the very low proportion in
our study (23%) with follow-up Western blot testing. Some
practitioners recommend using a DNA polymerase chain reaction
method to test for infection in a pregnant woman with
indeterminate results, but these tests are not currently approved
by the FDA for diagnostic purposes, may not be available, are
expensive, and require skilled technicians (5). A person with a
reactive EIA and Western blot negative or indeterminate result
may have an approved nucleic acid amplification test, and if
positive, can be considered infected, but further serologic testing is
required for a person with a reactive EIA and negative nucleic acid
test results (APTIMA HIV-1 RNA Qualitative Assay, GEN-
PROBE, San Diego, CA). Also, although nucleic acid testing is
sensitive for detecting early infection, it is less sensitive for the
detection of established infection than serologic tests [19,20].
Pregnant women with reactive HIV EIA results would benefit from
a testing algorithm which would accurately rule-out HIV infection
status in a timely way before the onset of labor, without the provision
of indeterminate results which may cause undue stress in someone
who isnot infected.It isnot yet known whether analgorithm using two
antibody EIAs with different antigen or binding properties in series
could be used in pregnant women with a reactive screening result or
whether both EIAs would have concurrent non-specific reactivity in
uninfected persons [13]. It is ideal to establish HIV infection status
before a pregnant woman goes into labor, but if infection status is
unknown at the time of labor, a rapid test is conducted, and if positive,
antiretroviral therapy is recommended [21].
This study was subject to several limitations. Study participants
could have been included in the study more than one time, but it is
unlikely that de-duplicating would impact the findings, as few
subjects repeated testing even when this testing was recommended.
Persons with negative EIA results are unlikely to have had follow-up
testing, and slight changes to the large number of non-reactive tests
would have little impact on false-positive rates. Pregnant women
with false-positive HIV EIA screening results were more likely to
have recommended repeat testing, so if these follow-up specimens
were de-duplicated, the number of false-positives among pregnant
women would decrease and the rate would still be lower than that
among non-pregnant persons. The rate of false-positive EIAs in
pregnant women and others may vary by the EIA and supplemental
test used, although since the prevalence of HIV in pregnant women
in the US tends to be low, the predictive value of a positive EIA
screening test resultis likely to remainlow regardless of the screening
test used. There is a possibility of misclassification of pregnancy
status because few persons classified as pregnant had concomitant
pregnancy tests, however, most persons were categorized as
pregnantbased on anICD-9codeforpregnancy,somisclassification
is unlikely to be extensive, and HCG tests conducted on
prospectively collected specimens indicate that this misclassification
was likely very limited. Precise estimates of the proportion of
pregnantwomenand otherswithrepeatedlyreactive EIAresultsand
negative or indeterminate Western blot results which are truly
infected based on nucleic acid testing or other follow-up testing are
not available. The precision of the sensitivity analyses reported here
could be improved with better estimates of the rate of such
misclassification. Ideally, additional variables such as age and race
could have been included in a multivariable model examining false-
positive results by pregnancy status. The false positive rate was
statistically lower in persons younger than the median age, but the
difference was 2 in 10,000, which may not be meaningfully different,
so it may not be a strong confounder. Finally, 359 women with an
unspecified age should have been included in the pregnancy
unknown category instead of the not pregnant category, but they
could not be re-categorized because we did not receive line level
data. However, they constituted approximately 0.03% of the not
pregnant group, so the impact of re-categorizing their pregnancy
status on study findings would be negligible.
Approximately 70% of pregnant women in the United States
receive prenatal antibody screening for HIV infection, and increasing
this proportion is necessary given that approximately one quarter of
new HIV infections occur among women, many of whom are of
child-bearing age [22,23]. False-positive antibody EIA test results are
rare, so universal HIV screening among pregnant women should be
pursued without hesitation unless a woman declines [2]. However,
clinicians should be aware that when HIV prevalence is low, as is
often the case among pregnant women in the United States, a
reactive EIA resultis morelikelyto be false-positive. Testing strategies
that allow for more timely and accurate identification of false-positive
HIV antibody test results should be considered for low prevalence
populations, including pregnant women [13].
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